Department of Clinical Pharmacology, School of Medicine, Flinders University, Australia.
Br J Clin Pharmacol. 2010 Jun;69(6):689-700. doi: 10.1111/j.1365-2125.2010.03627.x.
We studied the association between either non-selective NSAIDs (ns-NSAIDs), selective COX-2 inhibitors, or any NSAID and risk of incident myocardial infarction (MI) and heart failure (HF), and all-cause mortality in elderly subjects.
We conducted a retrospective nested case-control study on Australian veterans using nationwide hospital admission and pharmacy dispensing data. We estimated adjusted odds ratios (OR) with 95% confidence intervals (CI) for the risk of events for three different measures of prescription supply exposure over the last 2 years: (i) supplied at least once, (ii) supply frequency: supplied more than twice within the last 30 days, once or twice within the last 30 days, and once or more 30 days to 2 years and (iii) total supplies.
We identified 83 623 cases and 1 662 099 matched controls (1:20) contributing 3 862 931 persons-years of observation. NSAID use at least once within the last 2 years did not significantly affect the risk of MI (OR 1.00, 95% CI 0.96, 1.04) but was associated with a mildly reduced risk of HF (OR 0.95, 95% CI 0.92, 0.98). There was a reduced all-cause mortality with at least one supply of either ns-NSAIDs (OR 0.94, 95% CI 0.90, 0.97), selective COX-2 inhibitors (OR 0.90, 95% CI 0.88, 0.93), or any NSAID (OR 0.87, 95% CI 0.85, 0.90). Risk of death was also inversely associated with the number of prescription supplies.
NSAID use is not associated with an increased risk of incident MI and HF but is associated with a reduction in all-cause mortality in Australian veterans.
我们研究了非选择性非甾体抗炎药(ns-NSAIDs)、选择性环氧化酶-2 抑制剂或任何 NSAID 与老年患者新发心肌梗死(MI)和心力衰竭(HF)以及全因死亡率的相关性。
我们使用澳大利亚全国性的住院和药房配药数据,对退伍军人进行了回顾性巢式病例对照研究。我们估计了三种不同的处方供应暴露测量方法在过去 2 年内发生事件的风险的校正比值比(OR)和 95%置信区间(CI):(i)至少供应一次,(ii)供应频率:在过去 30 天内供应两次以上、一次或两次、一次或更多 30 天至 2 年,(iii)总供应量。
我们确定了 83623 例病例和 1662099 例匹配对照(1:20),共观察了 3862931 人年。在过去 2 年内至少使用一次 NSAID 不会显著增加 MI 的风险(OR 1.00,95%CI 0.96,1.04),但与 HF 风险略有降低相关(OR 0.95,95%CI 0.92,0.98)。至少有一次供应 ns-NSAIDs(OR 0.94,95%CI 0.90,0.97)、选择性 COX-2 抑制剂(OR 0.90,95%CI 0.88,0.93)或任何 NSAID(OR 0.87,95%CI 0.85,0.90)时,全因死亡率降低。处方供应数量与死亡风险呈反比。
NSAID 的使用与新发 MI 和 HF 的风险增加无关,但与澳大利亚退伍军人的全因死亡率降低相关。